seed
Stage
2
Investors
About
ReBio Pharma develops targeted, locally delivered therapies for ocular cancers such as uveal melanoma and retinoblastoma, utilizing their proprietary SiSu® therapeutic amplifier platform to enable precise, programmable drug release and retention in the eye.
Explore ReBio Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.